Therapeutics News and Research

RSS

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.

28 Jul 2015

CRINONE (progesterone gel) approved in nine new EU countries

Juniper Pharmaceuticals, Inc., a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE (progesterone gel) under the mutual-recognition procedure (MRP).

28 Jul 2015

Researchers use silk fibers to grow stem cells into salivary gland cells

The silkworm, which produces the essential ingredient for fine silk fabric, also plays a critical role in a new process designed to provide relief for millions of individuals with dry mouth, a devastating oral and systemic health issue.

28 Jul 2015

Innovative approach to treating AAT deficiency

Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)--which is missing or nonfunctional in the genetic disorder AAT deficiency--into cells in the laboratory, enabling the cells to produce highly functional AAT.

28 Jul 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

Multiple sclerosis relapse management: an interview with Gina Remington

MS relapses are typically reflective of new neurological symptoms. However, it can be a worsening of neurologic symptoms that begins after a patient has been stable (generally for about 30 days), but relapses are persistent and consistent changes in symptoms that occur for more than 24 to 48 hours.

26 Jul 2015

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

25 Jul 2015

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancreatitis. The paper, titled "Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models" appears in the August edition of the journal Gastroenterology.

25 Jul 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

23 Jul 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

The National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, director of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.

23 Jul 2015

Smokers who switch to low-nicotine cigarettes find difficult to curb smoking habits in the long term

Smokers who successfully lowered their nicotine intake when they were switched to low-nicotine cigarettes were unable to curb their smoking habits in the long term, according to a study by researchers at UCSF and San Francisco General Hospital and Trauma Center.

23 Jul 2015

Researchers develop dynamic smart drug that targets site-specific inflammation

Ben-Gurion University of the Negev and University of Colorado researchers have developed a dynamic "smart" drug that targets inflammation in a site-specific manner and could enhance the body's natural ability to fight infection and reduce side effects.

23 Jul 2015

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

22 Jul 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

An international panel of leading scientists is launching a new TripAdvisor-style website aimed at helping researchers choose better-quality research tools - and avoiding potentially serious errors in biomedical research.

22 Jul 2015

Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Dartmouth researchers and their colleagues have carried out the first total syntheses of certain compounds involved in excessive cell death in leukemia.

22 Jul 2015

Therapeutics News and Research

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

CRINONE (progesterone gel) approved in nine new EU countries

Researchers use silk fibers to grow stem cells into salivary gland cells

Innovative approach to treating AAT deficiency

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Multiple sclerosis relapse management: an interview with Gina Remington

Trends, R&D progress, and predicted revenues in RNAi therapies

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

SutroVax completes $22 million Series A financing

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

UC San Diego researchers receive NIH grant to test efficacy of Sanofi's pain drug in treating Chagas disease

Smokers who switch to low-nicotine cigarettes find difficult to curb smoking habits in the long term

Researchers develop dynamic smart drug that targets site-specific inflammation

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

Dartmouth researchers perform first total syntheses of compounds involved in rapid cell death in leukemia

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News